Table 2.
Studies of EUS-guided ablation using different agents
| Ref. | Year | No. of patients | Ablative agent | Mean/median diameter (mm) |
Diagnosis, n (%) |
Follow-up (mo) |
Treatment effectiveness, n (%) |
No. of complications, n (%) | ||||
| SCN | MCN | IPMN | Others | CR | PR | |||||||
| Gan et al[14] | 2005 | 25 | 5%-80% ethanol | 19.4 | 3 (12) | 13 (52) | 4 (16) | 5 (20) | 12 | 8 (34.8) | 2 (8.7) | 0 |
| DeWitt et al[35] | 2009 | 42 | 80% ethanol vs saline | 22.4 | 5 (11.9) | 17 (40.5) | 17 (40.5) | 3 (7.1) | 3-4 mo after second lavage | 12 (33.3) | NA | 12 (28.6): 10 (abdominal pain), 1 (intracys-tic hemorrhage), 1 (pancreatitis) |
| DiMaio et al[32] | 2011 | 13 | 80% ethanol | 20.1 | 0 | 0 | 13 (100) | 0 | 3-6 mo after second lavage | 5 (38.4) | NA | 1 (7.7): 1 (abdomin-al pain) |
| Caillol et al[33] | 2012 | 13 | 99% ethanol | 24 | 0 | 13 (100) | 0 | 0 | 26 | 11 (84.6) | NA | 0 |
| Gómez et al[25] | 2016 | 23 | 80% ethanol | 27.5 | 0 | 4 (17.4) | 19 (82.6) | 0 | 40 | 2 (8.7) | NA | 2 (8.8): 1 (abdominal pain), 1 (pancreatitis) |
| Park et al[16] | 2016 | 91 | 99% ethanol | 58 | 33 (36.3) | 12 (13.2) | 9 (9.9) | 37 (40.6) | 40 | 41 (45.1) | 37 (40.7) | 29 (31.9): 18 (abdominal pain), 8 (fever), 3 (pancreatitis) |
| Oh et al[5] | 2008 | 14 | 99% ethanol + paclitaxel | 25.5 | 3 (21.5) | 2 (14) | NA | 9 (64.5) | 9 | 11 (78.6) | 2 (14.3) | 8 (57.1): 1 (pancreatitis), 1 (abdominal pain), 6 (hyperamylasemia) |
| Oh et al[31] | 2009 | 10 | 99% ethanol + paclitaxel | 29.5 | 4 (40) | 3 (30) | 3 (30) | 0 | 8.5 | 6 (60.0) | 2 (20.0) | 1 (10): 1 (pancreatitis) |
| Oh et al[15] | 2011 | 52 | 99% ethanol + paclitaxel | 31.8 | 15 (29) | 9 (17) | NA | 28 (54) | 20 | 29 (61.7) | 6 (12.8) | 4 (7.7): 1 (pancreatitis), 1 (abdominal pain), 1 (fever), 1 (splenic vein obliteration) |
| Oh et al[28] | 2014 | 10 | 99% ethanol + paclitaxel | 39.5 | NA | NA | NA | NA | 12 | NA | NA | 7 (70): 5 (abdominal pain), 1 (vomiting), 1 (intracystic bleeding) |
| DeWitt et al[26] | 2014 | 22 | 99% ethanol + paclitaxel | 24 | 4 (18) | 6 (27) | 12 (55) | 0 | 27 | 10 (50.0) | 5 (25.0) | 9 (40.1): 4 (abdomin-al pain), 3 (pancreatitis), 1 (peritonitis), 1 (gastric wall cyst) |
| Kim et al[27] | 2017 | 36 | 100% ethanol or (ethanol + paclitaxel) | 25.8 | 5 (13.9) | 16 (44.4) | 14 (38.9) | 1 (2.8) | 22.3 | 19 (55.9) | 7 (19.4) | 9 (25): 4 (pancreatitis), 4 (abdominal pain), 1 (intracystic hemorrhage) |
| Choi et al[29] | 2017 | 164 | 99% ethanol + paclitaxel | 32 | 16 (9.8) | 71 (43.3) | 11 (6.1) | 66 (40.2) | 72 | 114 (72.2) | 31 (19.6) | 15 (9.1): 6 (pancreatitis), 2 (pseudocyst), 2 (abscess), 1 (intracystic hemorrhage), 1 (pericystic spillage), 1 (pancreatic duct stricture), 1 (splenic vein obstruction), 1 (portal vein thrombosis) |
| Linghu et al[2] | 2017 | 29 | Lauromacrogol | 28.6 | 12 (41.4) | 15 (51.7) | 0 | 2 (6.9) | 9 | 11 (37.9) | 9 (31.0) | 3 (8.3): 2 (pancreatitis), 1 (fever) |
| Moyer et al[34] | 2016 | 10 | 80% ethanol or Saline + paclitaxel and gemcitabine | 29 | 0 | 7 (70%) | 2 (20%) | 1 (10%) | 12 | Ethanol free 4 (66.7) ethanol 3 (75.0) | NA | 1 (10): 1 (pancreatitis) |
| Moyer et al[18] | 2017 | 39 | 80% ethanol or saline + paclitaxel and gemcitabine | 25 | 0 | 9 (23.1) | 27 (69.2) | 3 (7.7) | 12 | Ethanol free arm 14 (66.7) ethanol arm 11 (61.1) | NA | 5 (12.8): 4 (abdominal pain), 1 (pancreatitis) |
SCN: Serous cystic neoplasm; MCN: Mucinous cystic neoplasm; IPMN: Intraductal papillary neoplasm; CR: Complete response; PR: Partial complete; NA: Not available.